Literature DB >> 11328777

Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus.

A J O'Neill1, J H Cove, I Chopra.   

Abstract

Frequencies at which mutants resistant to fusidic acid and/or rifampicin arose in vitro were determined in Staphylococcus aureus strains including methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), vancomycin-intermediate resistant S. aureus (VISA) and hetero-VISA. The concentrations of fusidic acid (30 and 15 mg/L) and rifampicin (16 and 1 mg/L) used for selection were equal to the expected maximum and minimum serum concentrations after an oral regimen of rifampicin 900 mg od, together with fusidic acid 500 mg tds. Resistant mutants arose at a frequency of around 10(-8) for selections with rifampicin, but were undetectable (frequency <10(-11)) for selections with fusidic acid. Mutants were not recovered (frequency <10(-11)) after selections in the presence of both fusidic acid and rifampicin at 30/16 and 15/1 mg/L. Our results suggest that these antibiotics, when used in combination, could have a wider role in the management of staphylococcal infections.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328777     DOI: 10.1093/jac/47.5.647

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  32 in total

1.  Lack of evidence for involvement of hypermutability in emergence of vancomycin-intermediate Staphylococcus aureus.

Authors:  Alexander J O'Neill; Ian Chopra
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains.

Authors:  A Doléans-Jordheim; E Bergeron; F Bereyziat; S Ben-Larbi; O Dumitrescu; M-A Mazoyer; F Morfin; C Dumontet; J Freney; L P Jordheim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-15       Impact factor: 3.267

3.  In vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus.

Authors:  Hung-Jen Tang; Chi-Chung Chen; Kuo-Chen Cheng; Kuan-Ying Wu; Yi-Chung Lin; Chun-Cheng Zhang; Tzu-Chieh Weng; Wen-Liang Yu; Yu-Hsin Chiu; Han-Siong Toh; Shyh-Ren Chiang; Bo An Su; Wen-Chien Ko; Yin-Ching Chuang
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

Review 4.  Molecular imaging of bacterial infections: Overcoming the barriers to clinical translation.

Authors:  Alvaro A Ordonez; Mark A Sellmyer; Gayatri Gowrishankar; Camilo A Ruiz-Bedoya; Elizabeth W Tucker; Christopher J Palestro; Dima A Hammoud; Sanjay K Jain
Journal:  Sci Transl Med       Date:  2019-09-04       Impact factor: 17.956

5.  A bactericidal guanidinomethyl biaryl that alters the dynamics of bacterial FtsZ polymerization.

Authors:  Malvika Kaul; Ajit K Parhi; Yongzheng Zhang; Edmond J LaVoie; Steve Tuske; Eddy Arnold; John E Kerrigan; Daniel S Pilch
Journal:  J Med Chem       Date:  2012-10-26       Impact factor: 7.446

Review 6.  Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal Infections.

Authors:  Prabhavathi Fernandes
Journal:  Cold Spring Harb Perspect Med       Date:  2016-01-04       Impact factor: 6.915

7.  An FtsZ-targeting prodrug with oral antistaphylococcal efficacy in vivo.

Authors:  Malvika Kaul; Lilly Mark; Yongzheng Zhang; Ajit K Parhi; Edmond J Lavoie; Daniel S Pilch
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

Review 8.  Rifampin-accompanied antibiotic regimens in the treatment of prosthetic joint infections: a frequentist and Bayesian meta-analysis of current evidence.

Authors:  Ozlem Aydın; Pinar Ergen; Burak Ozturan; Korhan Ozkan; Ferhat Arslan; Haluk Vahaboglu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-30       Impact factor: 3.267

9.  A timescale for evolution, population expansion, and spatial spread of an emerging clone of methicillin-resistant Staphylococcus aureus.

Authors:  Ulrich Nübel; Janina Dordel; Kevin Kurt; Birgit Strommenger; Henrik Westh; Sanjay K Shukla; Helena Zemlicková; Raphaël Leblois; Thierry Wirth; Thibaut Jombart; François Balloux; Wolfgang Witte
Journal:  PLoS Pathog       Date:  2010-04-08       Impact factor: 6.823

10.  Frequency, spectrum, and nonzero fitness costs of resistance to myxopyronin in Staphylococcus aureus.

Authors:  Aashish Srivastava; David Degen; Yon W Ebright; Richard H Ebright
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.